Core Insights - Insmed Inc has outlined a commercial and clinical roadmap for 2026, emphasizing strong momentum from its respiratory portfolio and upcoming trial readouts and launches that could significantly impact growth over the next 18 months [1] Financial Performance - Insmed reported preliminary revenues of $172.7 million for Brinsupri in full-year 2025, with approximately $144.6 million generated in the first full quarter post-FDA approval in August 2025 [2] - The company forecasts global sales for Arikayce to be between $450 million and $470 million in 2026, with preliminary sales of approximately $433.8 million for 2025 [4] Product Launches and Approvals - Brinsupri, a treatment for non-cystic fibrosis bronchiectasis, received European Commission approval in November 2025 and is set for launch in the EU in the first half of 2026, with additional launches planned in the U.K. and Japan [3][4] - Insmed is advancing brensocatib in hidradenitis suppurativa, with Phase 2b CEDAR study data expected in Q2 2026 [6] Upcoming Catalysts - The company anticipates topline results from the Phase 3 ENCORE trial of Arikayce by March or April 2026, with plans to submit a supplemental NDA to the FDA if successful [5] - Insmed initiated a Phase 3 trial in PH-ILD in late 2025 and plans to start a Phase 3 PAH study in early 2026 [6] Pipeline Developments - The neuro pipeline includes a Phase 1 ASCEND trial for Duchenne muscular dystrophy and a Phase 1 ARMOR study for amyotrophic lateral sclerosis, with an IND filing planned for Stargardt disease in 2026 [7] - Insmed's preclinical engine consists of over 30 programs, with expectations to file one to two INDs annually while maintaining preclinical spending below 20% of total expenditures [7] Recent Study Results - The Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints [8]

Core Insights - Insmed's shares fell nearly 20% in after-market trading following the failure of the mid-stage BiRCh study for Brinsupri in chronic rhinosinusitis without nasal polyps [1][7] - The BiRCh study did not meet its primary or secondary efficacy endpoints, leading to the decision to halt Brinsupri's development in this indication [2][7] - Investors were surprised by the negative results, especially after Insmed's recent success with Brinsupri's approval for non-cystic fibrosis bronchiectasis [3][6] Company Performance - Despite the setback, Insmed's shares are still up 187% year-to-date, significantly outperforming the industry average growth of 18% [6] - Brinsupri generated $28 million in sales during Q3 2025, indicating strong initial market uptake [4] - The failure of the BiRCh study has dampened investor enthusiasm for the ongoing phase II CEDAR study for Brinsupri in hidradenitis suppurativa, with results expected in the first half of 2026 [5] Pipeline Expansion - Insmed announced the acquisition of investigational monoclonal antibody INS1148 from Opsidio, aimed at treating respiratory and immunological diseases [9] - The company plans to develop INS1148 in mid-stage studies for interstitial lung disease and moderate-to-severe asthma [9]

Core Insights - Insmed (INSM) received European Commission approval for Brinsupri (brensocatib) to treat non-cystic fibrosis bronchiectasis (NCFB), leading to a 2.1% increase in share price [1][6] - Brinsupri is the first and only approved treatment for NCFB in the EU, having undergone accelerated assessment by the European Medicines Agency (EMA) due to its public health significance [2][3] - Year-to-date, Insmed's shares have surged by 192%, significantly outperforming the industry average increase of 15.7% [2] Regulatory Approval - The approval of Brinsupri was based on comprehensive scientific reviews, including data from phase III ASPEN and phase II WILLOW studies [3] - The ASPEN study demonstrated that Brinsupri (25 mg) reduced the annual exacerbation rate by 19.4% compared to placebo, while also meeting key secondary goals [4][6] Commercial Performance - In the third quarter of 2025, Brinsupri generated sales of $28.1 million in the partial quarter following its U.S. approval and launch, indicating a promising commercial start [8] Future Developments - Insmed is also exploring Brinsupri in the phase IIb BiRCh study for chronic rhinosinusitis without nasal polyps (CRSsNP), with data expected in early 2026, and in the phase II CEDAR study for hidradenitis suppurativa, with top-line data anticipated in the first half of 2026 [9]